October 10, 2016 by Geoff Walden and Chain Drug Review
CVS, Federal Trade Commission, FTC, Kroger, Rite Aid, Stefano Pessina, Walgreens, Walgreens Boots Alliance, WBA, WBA-Rite Aid
2016, Issue 10-10-2016, Issues, News
NEW YORK — Speculation continues to percolate about snags holding up Walgreens Boots Alliance Inc.’s (WBA’s) acquisition of Rite Aid Corp. Last last month the New York Post reported that private equity firms were uninterested in purchasing 650 stores that WBA must divest to satisfy antitrust requirements. Investors found the stores to be subpar and
September 12, 2016 by John Schultz and Chain Drug Review
Alex Gourlay, EnvisionRx, prescription drug market, Prime Therapeutics, Rite Aid, Stefano Pessina, Walgreens Boots Alliance
2016, Issue 09-12-2016, Issues, News
DEERFIELD, Ill. — The partnership of Walgreens Boots Alliance Inc. (WBA) and pharmacy benefit manager Prime Therapeutics positions the companies to capture a larger share of the prescription drug market and better compete with such players as CVS Health. St. Paul, Minn.-based Prime, the nation’s fourth-largest PBM with 22 million members, is owned by 14
September 12, 2016 by Chain Drug Review
AmerisourceBergen, Stefano Pessina, Walgreens Boots Alliance
2016, Issue 09-12-2016, Issues, News
DEERFIELD, Ill. — Walgreens Boots Alliance (WBA) Inc. has raised its stake in AmerisourceBergen Corp. to nearly 24%. Late last month, WBA exercised warrants to buy 22,696,912 shares of AmerisourceBergen common stock for about $1.19 billion. The warrants, the second of two tranches, are part of a long-term partnership announced in March 2013 between AmerisourceBergen
September 8, 2016 by Chain Drug Review
Federal Trade Commission, Rite Aid, Stefano Pessina, Walgreens Boots Alliance
Business, Featured Articles, Leading Headlines, Retail News
DEERFIELD, Ill. — Walgreens Boots Alliance (WBA) said it’s working on store divestiture scenarios with the Federal Trade Commission to gain clearance for its $17.2 billion deal to acquire Rite Aid Corp. WBA said Thursday that it and Rite Aid “remain actively engaged” in talks with the FTC as the regulator reviews the acquisition, which
August 26, 2016 by Chain Drug Review
AmerisourceBergen Drug Corp., Stefano Pessina, Walgreens Boots Alliance
Featured Articles, Leading Headlines, Retail News
DEERFIELD, Ill. — Walgreens Boots Alliance Inc. said on Friday that it had agreed with AmerisourceBergen Corp. to amend the second tranche of warrants held by WBA to purchase AmerisourceBergen common stock to allow immediate exercise of the warrants, giving WBA nearly 24% of AmerisourceBergen’s outstanding equity. The warrants were originally scheduled to be exercisable
August 6, 2016 by Jeffrey Woldt and Chain Drug Review
Ahold, Delhaize, Federal Trade Commission, Jeffrey Woldt, Ornella Barra, Rite Aid, Stefano Pessina, Walgreens, Walgreens Boots Alliance, Walgreens-Rite Aid merger, WBA
2016, Featured Articles, Issue 08-08-2016, Issues, Leading Headlines, Opinion
It has been slightly more than nine months since Walgreens Boots Alliance agreed to acquire Rite Aid in a $17.2 billion all-cash transaction. Since that time, speculation about whether the Walgreens-Rite Aid merger will pass muster with the Federal Trade Commission has become a staple of discussion for people involved in community pharmacy and the
July 15, 2016 by CDR Blog
Federal Trade Commission, FTC, Rite Aid, Scott Mushkin, Stefano Pessina, Walgreens Boots Alliance, Wolfe Research
CDR Blog, Leading Headlines
It looks like Walgreens Boots Alliance is getting down to brass tacks in its negotiations with the Federal Trade Commission to acquire Rite Aid. The New York Post reported late Thursday evening that WBA is discussing store divestitures with the FTC and trying to get a bead on the number of Walgreens and/or Rite Aid
July 6, 2016 by CDR Blog
Rite Aid, Stefano Pessina, Walgreens Boots Alliance, WBA
CDR Blog, Leading Headlines
Stefano Pessina said Walgreens Boots Alliance remains in the ballpark in terms of likely store divestitures that the Federal Trade Commission will require for WBA to finalize its deal to acquire Rite Aid Corp. “We still believe that our initial estimate is correct. We still believe that at the end we will stay in the
July 6, 2016 by Chain Drug Review
Alliance Boots, AmerisourceBergen, Stefano Pessina, Walgreens, Walgreens Boots Alliance, WBA
Business, Featured Articles, Leading Headlines, Retail News
DEERFIELD, Ill. — Walgreens Boots Alliance (WBA) saw sales and adjusted net earnings rise in its fiscal 2016 third quarter, with adjusted earnings per share exceeding Wall Street’s consensus forecast. WBA said Wednesday that its pending acquisition of Rite Aid Corp. remains on track for completion in the second half of this year, and it
June 20, 2016 by Geoff Walden and Chain Drug Review
Alex Gourlay, Boots, Elizabeth Fagan, Kathleen Wilson-Thompson, Ken Murphy, Ornella Barra, Richard Ashworth, Rite Aid, Simon Roberts, Stefano Pessina, Walgreens, Walgreens Boots Alliance, WBA
2016, Issue 06-20-2016, Issues, News
DEERFIELD, Ill. — Alex Gourlay and Ornella Barra have been named co-chief operating officers of Walgreens Boots Alliance Inc. (WBA). Gourlay had been president of Walgreens, and Barra president and chief executive of global wholesale and international retail. Both had also been executive vice presidents of WBA. In his new role, Gourlay will oversee Walgreens
June 20, 2016 by Jeffrey Woldt and Chain Drug Review
Alex Gourlay, AmerisourceBergen, Boots, Jeffrey Woldt, Ornella Barra, Rite Aid, Stefano Pessina, Walgreens, Walgreens Boots Alliance, WBA
2016, Featured Articles, Issue 06-20-2016, Issues, Leading Headlines, Opinion
The appointment of Alex Gourlay and Ornella Barra as co-chief operating officers of Walgreens Boots Alliance signals the start of a new stage in the process of forging the two companies that came together to form WBA at the close of 2014 into a new corporate culture. The two executives, whose talent, experience and leadership
June 6, 2016 by Chain Drug Review
Barry Rosenstein, James Skinner, JANA Partners, Stefano Pessina, Walgreens Boots Alliance
2016, Issue 06-06-2016, Issues, News
DEERFIELD, Ill. — Activist investor Barry Rosenstein, managing partner of hedge fund JANA Partners LLC, has stepped down from the Walgreens Boots Alliance Inc. (WBA) board after reducing his investment in the company. WBA said Rosenstein, who had been a director since September 2014, was slated to end his service on the board once JANA’s
May 23, 2016 by Chain Drug Review
Barry Rosenstein, Dominic Murphy, James Skinner, JANA Partners, KKR, Kohlberg Kravis Roberts, Stefano Pessina, Walgreens Boots Alliance, WBA
Business, Leading Headlines, Retail News
DEERFIELD, Ill. — Activist investor Barry Rosenstein, managing partner of hedge fund JANA Partners LLC, has stepped down from the Walgreens Boots Alliance (WBA) Inc. board after reducing his investment in the company. WBA said late Friday that Rosenstein, who has been a director since September 2014, was slated to end his service on the
April 5, 2016 by John Schultz and Chain Drug Review
AmerisourceBergen, Rite Aid, second quarter, Stefano Pessina, Walgreens, Walgreens Boots Alliance, WBA
Business, Featured Articles, Leading Headlines, Retail News
DEERFIELD, Ill. — Walgreens Boots Alliance (WBA) reported double-digit revenue growth for its fiscal 2016 second quarter, with adjusted earnings per share topping Wall Street’s consensus forecast. WBA said Tuesday that second-quarter sales climbed 13.6% to $30.18 billion from $26.57 billion a year earlier. The gain stemmed largely from the full consolidation of Alliance Boots